12:00 AM
Feb 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SPN810: Phase IIa started

Supernus began an open-label, U.S. Phase IIa trial to evaluate oral SPN810 in up to 72 patients.


Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >